37 completed, 7 terminated, 5 withdrawn, 3 active not recruiting. 21 Phase 2, 10 Phase 1, 9 Not applicable, 5 Phase 3, 1 Early Phase 1.
Follow Leukemia, Mast-Cell: new trials by email Literature Review of Leukemia, Mast-Cell trials Research Report on Leukemia, Mast-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies BLU-263, Azacitidine - Advanced Systemic Mastocytosis | Phase 1 | Terminated | Blueprint Medicines Corporation | 9 | 2023-09-25 | 2025-04-10 |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis bezuclastinib - Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN) | Phase 2 | Recruiting | Cogent Biosciences, Inc. | 140 | 2021-11-09 | 2026-09-15 |
| Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis | Completed | Blueprint Medicines Corporation | 317 | 2020-12-02 | 2022-01-10 | |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | GT Biopharma, Inc. | 12 | 2020-01-01 | 2022-11-10 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 45 | 2019-08-29 | 2026-09-25 |
| (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Avapritinib - Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis | Phase 2 | Completed | Blueprint Medicines Corporation | 107 | 2018-11-21 | 2026-10-20 |
| (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Avapritinib - Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease | Phase 1 | Completed | Blueprint Medicines Corporation | 86 | 2016-03-10 | 2023-03-17 |
| Mast Cell Connect: A Registry for Patients With Mastocytosis Mastocytosis | Completed | Blueprint Medicines Corporation | 743 | 2015-11-01 | 2021-02-04 | |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 282 | 2015-11-01 | 2023-12-13 |
| Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Ibrutinib - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Terminated | Jason Robert Gotlib | 4 | 2015-03-01 | 2018-09-20 |
| Patient-Reported Outcome Questionnaire for Systemic Mastocytosis Interview - Aggressive Systemic Mastocytosis (ASM), SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | Completed | Adelphi Values LLC | 5 | 2014-07-01 | 2017-01-10 | |
| Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Brentuximab vedotin - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Completed | Jason Robert Gotlib | 10 | 2013-09-01 | 2019-01-29 |
| Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia bioelectric impedance analysis - Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Not applicable | Completed | Wake Forest University Health Sciences | 102 | 2013-07-01 | 2020-08-13 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications - Cancer | Unknown | Institut Català d'Oncologia | 96 | 2010-12-01 | 2013-08-12 | |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer massage therapy, questionnaire administration, quality-of-life assessment - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Wake Forest University Health Sciences | 80 | 2010-04-01 | 2018-07-02 |
| Registry of Older Patients With Cancer Chronic Myeloproliferative Disorders, Cognitive/Functional Effects | Recruiting | UNC Lineberger Comprehensive Cancer Center | 3000 | 2009-09-01 | 2026-06-29 |
Showing 20 of 60. Sign in to see all of them.
Leukemia, Biphenotypic, Acute (41) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (41) · Leukemia, Lymphocytic, Chronic, B-Cell (38) · Leukemia, Myeloid, Acute (37) · Leukemia, Hairy Cell (36) · Leukemia, Large Granular Lymphocytic (36) · Leukemia, Myelomonocytic, Chronic (35) · Burkitt Lymphoma (34) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (33) · Leukemia, Prolymphocytic (33) · Lymphoma, Large-Cell, Anaplastic (33) · Mycosis Fungoides (33) · Sezary Syndrome (33) · Immunoblastic Lymphadenopathy (32)
Hemic and Lymphatic Diseases (60) · Neoplasms by Histologic Type (60) · Hematologic Diseases (59) · Immune System Diseases (59) · Mast Cell Activation Disorders (59) · Leukemia, Myeloid (58) · Mastocytosis (57) · Neoplasms (52) · Immunoproliferative Disorders (44) · Lymphatic Diseases (44) · Mastocytosis, Systemic (44) · Bone Marrow Diseases (43) · Disease Attributes (42) · Leukemia, Lymphoid (42) · Pathologic Processes (42)
Whole-Body Irradiation (6) · fludarabine phosphate (6) · Cyclosporine (5) · Mycophenolic Acid (5) · Therapeutics (5) · Peripheral Blood Stem Cell Transplantation (4) · Psychiatric Rehabilitation (4) · midostaurin (3) · Busulfan (2) · Cyclophosphamide (2) · Darbepoetin alfa (2) · Early Intervention, Educational (2) · Methotrexate (2) · Pentetic Acid (2) · Sunitinib (2)
Fred Hutchinson Cancer Center (6) · Blueprint Medicines Corporation (5) · M.D. Anderson Cancer Center (4) · Wake Forest University Health Sciences (4) · Jason Robert Gotlib (3) · National Cancer Institute (NCI) (3) · Novartis Pharmaceuticals (3) · UNC Lineberger Comprehensive Cancer Center (3) · Asan Medical Center (2) · Case Comprehensive Cancer Center (2) · Children's Oncology Group (2) · City of Hope Medical Center (2) · Cogent Biosciences, Inc. (2) · Mayo Clinic (2) · Vanderbilt-Ingram Cancer Center (2)
United States (48) · Germany (7) · United Kingdom (7) · Canada (6) · Italy (6) · Netherlands (5) · Spain (5) · Austria (4) · France (4) · Norway (4) · Australia (3) · Belgium (3) · Poland (3) · South Korea (2) · Switzerland (2)
David Maloney (2) · Elisabeth Paietta, PhD (2) · Jason Gotlib (2) · Jorge Cortes, MD (2) · Kyoo H. Lee, MD (2) · Adam J. Esbenshade, MD (1) · Ann Woolfrey (1) · Anthony F. Shields, MD, PhD (1) · Anthony L Boral, MD, PhD (1) · Aprille Seidel, PhD (1) · Barbara A. Murphy, MD (1) · Barry J.A. Laird, MD (1) · Brenda Sandmaier (1) · Charles L. Loprinzi, M.D. (1) · Charles L. Loprinzi, MD (1)
PMID 35790816, PMID 27355533, PMID 32499241, PMID 35640224, PMID 18327587, PMID 18698002, PMID 19451433, PMID 21523798, PMID 22259028, PMID 22563089, PMID 24474568, PMID 26175532, PMID 26700120, PMID 26700123, PMID 28744009, PMID 30205939, PMID 31350306, PMID 32437738, PMID 32804590, PMID 33049057, PMID 34873345, PMID 34873347, PMID 39649724, PMID 41604606
P30CA015704 (5), P01CA018029 (3), P30CA015083 (2), P30CA016086 (2), P30CA068485 (2), P30CA072720 (2), 2008 (1), 2015 (1), 2017 (1), N01CM62202 (1), P01CA049605 (1), P01CA078902 (1), P30CA006973 (1), P30CA012197 (1), P30CA016672 (1)